Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study

M. Nardi, S. De Marco, A. Fabi, A. Aloe, E. Magnani, U. Pacetti, P. Carlini, E. M. Ruggeri, F. Cognetti

Research output: Contribution to journalArticle

Abstract

Purpose: The combination of paclitaxel and cisplatin is considered the standard regimen for advanced ovarian cancer (AOC). A meta-analysis has shown that the incorporation of anthracyclines into first-line chemotherapy might improve long-term survival by 7-10%. We designed a phase I-II study in patients with AOC using a combination of a fixed close of cisplatin with paclitaxel and epirubicin both given at escalating doses every 3 weeks. The objectives of this study were to determine both the maximum tolerated dose (MTD) and the antitumor activity of this combination. Methods: Six different dose levels were planned. The starting doses were cisplatin 75 mg/m2, paclitaxel 140 mg/m2, and epirubicin 50 mg/m2. The doses of paclitaxel were escalated in 20-mg/m2 increments, alternating with 20-mg/m2 increments of epirubicin. Ten patients with AOC entered the phase I study. Three patients each were enrolled at level I and level II and four patients at level III, and at each level, 15 courses were administered. Patients received a median of five courses. Results: Nonhematological toxicity was generally mild, except for grade 3 mucositis in one course at levels II and III, and grade 3 vomiting in one course at levels I and III. Hematological toxicities were grade 3-4 neutropenia in 60%, 47% and 60% of courses at levels I, II and III, respectively, and grade 3 anemia in one course at level III. At level III two of four patients developed a dose-limiting toxicity which was grade 4 neutropenia lasting more than 1 week. Conclusions: The MTD was reached at level II with cisplatin 75 mg/m2. paclitaxel 160 mg/m2, and epirubicin 50 mg/m2. The phase II part of the study is currently ongoing.

Original languageEnglish
Pages (from-to)255-258
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume48
Issue number3
DOIs
Publication statusPublished - 2001

Fingerprint

Epirubicin
Paclitaxel
Ovarian Neoplasms
Cisplatin
Toxicity
Maximum Tolerated Dose
Neutropenia
Chemotherapy
Anthracyclines
Mucositis
Vomiting
Meta-Analysis
Anemia
Drug Therapy
Survival

Keywords

  • Advanced ovarian cancer
  • Epirubicin
  • Ovarian cancer
  • Taxol

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study. / Nardi, M.; De Marco, S.; Fabi, A.; Aloe, A.; Magnani, E.; Pacetti, U.; Carlini, P.; Ruggeri, E. M.; Cognetti, F.

In: Cancer Chemotherapy and Pharmacology, Vol. 48, No. 3, 2001, p. 255-258.

Research output: Contribution to journalArticle

Nardi, M. ; De Marco, S. ; Fabi, A. ; Aloe, A. ; Magnani, E. ; Pacetti, U. ; Carlini, P. ; Ruggeri, E. M. ; Cognetti, F. / Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study. In: Cancer Chemotherapy and Pharmacology. 2001 ; Vol. 48, No. 3. pp. 255-258.
@article{ddd2e5dff7d94ed5bd602b8d842164e3,
title = "Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study",
abstract = "Purpose: The combination of paclitaxel and cisplatin is considered the standard regimen for advanced ovarian cancer (AOC). A meta-analysis has shown that the incorporation of anthracyclines into first-line chemotherapy might improve long-term survival by 7-10{\%}. We designed a phase I-II study in patients with AOC using a combination of a fixed close of cisplatin with paclitaxel and epirubicin both given at escalating doses every 3 weeks. The objectives of this study were to determine both the maximum tolerated dose (MTD) and the antitumor activity of this combination. Methods: Six different dose levels were planned. The starting doses were cisplatin 75 mg/m2, paclitaxel 140 mg/m2, and epirubicin 50 mg/m2. The doses of paclitaxel were escalated in 20-mg/m2 increments, alternating with 20-mg/m2 increments of epirubicin. Ten patients with AOC entered the phase I study. Three patients each were enrolled at level I and level II and four patients at level III, and at each level, 15 courses were administered. Patients received a median of five courses. Results: Nonhematological toxicity was generally mild, except for grade 3 mucositis in one course at levels II and III, and grade 3 vomiting in one course at levels I and III. Hematological toxicities were grade 3-4 neutropenia in 60{\%}, 47{\%} and 60{\%} of courses at levels I, II and III, respectively, and grade 3 anemia in one course at level III. At level III two of four patients developed a dose-limiting toxicity which was grade 4 neutropenia lasting more than 1 week. Conclusions: The MTD was reached at level II with cisplatin 75 mg/m2. paclitaxel 160 mg/m2, and epirubicin 50 mg/m2. The phase II part of the study is currently ongoing.",
keywords = "Advanced ovarian cancer, Epirubicin, Ovarian cancer, Taxol",
author = "M. Nardi and {De Marco}, S. and A. Fabi and A. Aloe and E. Magnani and U. Pacetti and P. Carlini and Ruggeri, {E. M.} and F. Cognetti",
year = "2001",
doi = "10.1007/s002800000271",
language = "English",
volume = "48",
pages = "255--258",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study

AU - Nardi, M.

AU - De Marco, S.

AU - Fabi, A.

AU - Aloe, A.

AU - Magnani, E.

AU - Pacetti, U.

AU - Carlini, P.

AU - Ruggeri, E. M.

AU - Cognetti, F.

PY - 2001

Y1 - 2001

N2 - Purpose: The combination of paclitaxel and cisplatin is considered the standard regimen for advanced ovarian cancer (AOC). A meta-analysis has shown that the incorporation of anthracyclines into first-line chemotherapy might improve long-term survival by 7-10%. We designed a phase I-II study in patients with AOC using a combination of a fixed close of cisplatin with paclitaxel and epirubicin both given at escalating doses every 3 weeks. The objectives of this study were to determine both the maximum tolerated dose (MTD) and the antitumor activity of this combination. Methods: Six different dose levels were planned. The starting doses were cisplatin 75 mg/m2, paclitaxel 140 mg/m2, and epirubicin 50 mg/m2. The doses of paclitaxel were escalated in 20-mg/m2 increments, alternating with 20-mg/m2 increments of epirubicin. Ten patients with AOC entered the phase I study. Three patients each were enrolled at level I and level II and four patients at level III, and at each level, 15 courses were administered. Patients received a median of five courses. Results: Nonhematological toxicity was generally mild, except for grade 3 mucositis in one course at levels II and III, and grade 3 vomiting in one course at levels I and III. Hematological toxicities were grade 3-4 neutropenia in 60%, 47% and 60% of courses at levels I, II and III, respectively, and grade 3 anemia in one course at level III. At level III two of four patients developed a dose-limiting toxicity which was grade 4 neutropenia lasting more than 1 week. Conclusions: The MTD was reached at level II with cisplatin 75 mg/m2. paclitaxel 160 mg/m2, and epirubicin 50 mg/m2. The phase II part of the study is currently ongoing.

AB - Purpose: The combination of paclitaxel and cisplatin is considered the standard regimen for advanced ovarian cancer (AOC). A meta-analysis has shown that the incorporation of anthracyclines into first-line chemotherapy might improve long-term survival by 7-10%. We designed a phase I-II study in patients with AOC using a combination of a fixed close of cisplatin with paclitaxel and epirubicin both given at escalating doses every 3 weeks. The objectives of this study were to determine both the maximum tolerated dose (MTD) and the antitumor activity of this combination. Methods: Six different dose levels were planned. The starting doses were cisplatin 75 mg/m2, paclitaxel 140 mg/m2, and epirubicin 50 mg/m2. The doses of paclitaxel were escalated in 20-mg/m2 increments, alternating with 20-mg/m2 increments of epirubicin. Ten patients with AOC entered the phase I study. Three patients each were enrolled at level I and level II and four patients at level III, and at each level, 15 courses were administered. Patients received a median of five courses. Results: Nonhematological toxicity was generally mild, except for grade 3 mucositis in one course at levels II and III, and grade 3 vomiting in one course at levels I and III. Hematological toxicities were grade 3-4 neutropenia in 60%, 47% and 60% of courses at levels I, II and III, respectively, and grade 3 anemia in one course at level III. At level III two of four patients developed a dose-limiting toxicity which was grade 4 neutropenia lasting more than 1 week. Conclusions: The MTD was reached at level II with cisplatin 75 mg/m2. paclitaxel 160 mg/m2, and epirubicin 50 mg/m2. The phase II part of the study is currently ongoing.

KW - Advanced ovarian cancer

KW - Epirubicin

KW - Ovarian cancer

KW - Taxol

UR - http://www.scopus.com/inward/record.url?scp=0034884286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034884286&partnerID=8YFLogxK

U2 - 10.1007/s002800000271

DO - 10.1007/s002800000271

M3 - Article

C2 - 11592349

AN - SCOPUS:0034884286

VL - 48

SP - 255

EP - 258

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -